Cofepris approved phase 3 of the German CureVac vaccine in Mexico

January 10, 2021 by No Comments


The Secretary of Foreign Affairs, Marcelo Ebrard, reported that phase 3 of the CureVac vaccine against coronavirus was authorized by the Federal Commission for Protection against Sanitary Risks (Cofepris).

Entrepreneur’s New Year’s Guide

Let the business resources in our guide inspire you and help you achieve your goals in 2021.


2 min read

This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.


This story originally appeared on Alto Nivel

CureVac is a biopharmaceutical company of German origin, Cofepris has already approved phase 3 tests for these doses.

Through his Twitter account, the Foreign Secretary announced that the federal agency of the Government of Mexico endorsed the final testing stage, phase 3 for the antidote to CureVac.

Image: @m_ebrard via Twitter

Similarly, the president expressed his gratitude on behalf of the Government of the Republic for the support of TecSalud , especially Dr. Guillermo Torre , to bring phase 3 of the vaccine developed by CUREVAC in Germany to Mexico .

Image: @m_ebrard via Twitter

What is known about the CureVac vaccine?

CureVac is a German biopharmaceutical company, according to information from the company that developed the vaccine , “thanks to the technology that we have generated mRNA , we can give the body the necessary information to fight and cure diseases . Driven by our passion, we want to use our technology to help patients and prolong people’s lives . “

That said, it is based on messenger mRNA, as is the case with Pfizer and BioNTech .

It is worth mentioning that Bayer and CureVac are in collaboration in the development of the coronavirus vaccine. Both companies have an agreement to support the production and commercialization of a messenger RNA vaccine to “facilitate the supply.”

Image: @CureVacRNA

In case you are interested: SRE: AstraZeneca Vaccine will arrive in Mexico on January 18



Source link

Please follow and like us:

Leave a Comment

Your email address will not be published. Required fields are marked *